FY24 Financial Results & Business Outlook
Released
Released
Announcement PDF
ASX Announcement
22 August 2024
FY24 Financial Results & Business Outlook
All figures in US$
Reporting Period: 30 June 2024. Prior Corresponding Period (PCP): 30 June 2023
Cogstate Ltd (ASX:CGS) has today released its Appendix 4E and Annual Report to Shareholders for the year ended
30 June 2024 (FY24). A summary of the FY24 result is provided below.
•
Group Revenue of $43.4m, up 7% on PCP
•
Group Profit before Tax of $7.1m, up 135% on PCP
•
Clinical Trials New Contract Sales of $27.0m, down 21% on PCP ($34.0m) but includes key achievements
for future growth including:
-
continued growth and diversification of the customer base in Alzheimer’s disease trials with three new
customers; and
-
60% growth on PCP in the value of sales contracts from indications outside of Alzheimer’s disease.
•
Contracted future revenue of $110.9m, down 16%.
•
Cash Flow/Balance Sheet: Positive cash flow from operations of $5.8m during FY24, compared to PCP of
$0.7m. Net cash balance at 30 June 2024 of $29.4m (gross cash less cash received in advance for future
pass-through costs).
•
Re-acquired global rights to technology previously licensed to Eisai enabling Cogstate to push digital
assessments directly into the community.
•
FY25 outlook: Strong start to FY25 with net new contracts executed of $9.3m as at 21st August (gross
contracts $29.6m), taking total revenue under contract to $110.9m, of which $33.6m relates to FY25.
Summary of FY24 Results (All figures are stated in US$)
MOVEMENT
30 June 2024
US$
43,427,773
30 June 2023
US$
40,451,123
US$
2,976,650
%
7
- Clinical Trials revenue
39,442,717
36,050,153
3,392,564
9
Total revenue from ordinary activities
- Healthcare revenue
3,985,057
4,400,970
(415,913)
(9)
EBITDA
9,259,214
4,801,277
4,457,937
93
Profit Before Tax
7,101,491
3,025,111
4,076,380
135
Net Profit After Tax
5,449,884
3,567,733
1,882,151
53
0.032
0.021
0.011
54
5,784,803
654,129
5,130,674
784
EPS
Net operating cash flow
FY24 Media Release | Page 1
FY24 Segment Reporting
Half Year
31 Dec 23
US$
Half Year
30 June 24
US$
Full Year 2024
US$
Full Year 2023*
US$
Revenue from operations
20,168,909
23,258,864
43,427,773
40,451,123
Clinical Trials
Revenue
17,920,459
21,522,257
39,442,717
36,050,153
Direct Cost (excluding direct depreciation)
(6,838,109)
(6,668,040)
(13,506,150)
(13,991,558)
Gross margin
11,082,350
14,854,217
25,936,567
22,058,595
SG&A
(2,061,870)
(2,143,848)
(4,205,718)
(4,326,716)
Clinical Trials Contribution
9,020,480
12,710,369
21,730,849
17,731,879
50%
59%
55%
49%
2,248,450
1,736,607
3,985,057
4,400,970
Contribution Margin
Healthcare
Revenue
Direct costs
(462,808)
(647,645)
(1,110,453)
(1,285,873)
Healthcare Contribution
1,785,642
1,088,961
2,874,603
3,115,097
79%
63%
72%
71%
(7,577,693)
(7,768,545)
(15,346,238)
(16,045,699)
Contribution Margin
Other operating costs
EBITDA
3,228,429
6,030,785
9,259,214
4,801,277
Depreciation and amortisation
(1,429,428)
(1,309,142)
(2,738,570)
(2,594,942)
Profit before tax, interest and other income
1,799,001
4,721,643
6,520,644
2,206,335
Net interest
292,185
288,662
580,847
666,040
Other Income
2,091,186
5,010,305
7,101,491
3,025,111
Net profit before tax
152,736
* Former segment, Research, is now part of the Clinical Trials segment. Prior year contracted future revenue for Research has
been included within Clinical Trials for comparison.
FY24 Media Release | Page 2
Explanatory Notes
1. Sales contracts: In the Clinical Trials division, Cogstate enters into contracts (“sales contracts”) with both
pharmaceutical and biotechnology companies for the provision of Cogstate technology and services, for use in
clinical research trials, to determine the extent to which their investigational compound is impacting the
cognition of the patient population. The contract value will differ for each clinical trial, depending upon the
scope of the technology and services provided by Cogstate, as well as the complexity and length of the trial.
An increase in the total value of sales contracts executed will increase the revenue backlog and will, over time,
result in an increase to revenue recognised by Cogstate.
2. Calculation of revenue from Clinical Trials division: Revenue from sales contracts is recognised over the
life of the contract. The length of a clinical trial can vary from several months for a phase 1 study and up to 4-5
years for a phase 3 study. Revenue is recognised based upon achievement of pre-determined milestones.
During each period, revenue may be recognised from (i) contracts in the backlog at the beginning of the period,
as well as (ii) sales contracts executed during the period. Usually there is a time lag between an increase or
decrease in the level of sales contracts executed and a corresponding change to recognised revenue.
3. Contracted future revenue backlog: Executed sales contract values that have not yet been recognised as
revenue at period end are referred to as “contracted future revenue”. The revenue from these contracts will be
recognised upon achievement of pre-determined milestones throughout the clinical trials. The contracted
future revenue figure provides insight into future revenue performance.
4. Healthcare revenue: Cogstate has developed tools specifically designed to aid healthcare professionals, in
general and specialist practice medicine, with objective assessments of cognition in patients. Cogstate’s
Healthcare offering includes the system branded as Cognigram™, a medical device which allows for regular
and standardised testing to assist in the early detection of cognitive decline that could be related to a range of
factors, including neurodegenerative diseases such as Alzheimer’s disease.
On 26 October 2020, Cogstate announced an exclusive global licensing agreement with pharmaceutical
company Eisai (was previously just Japan), under which Eisai will market Cogstate technology as digital
cognitive assessment tools targeting physicians, corporations, municipalities and also directly to consumers.
On 2 April 2024, Cogstate announced that it had amended its global license agreement with Eisai (the
“Amended Global License Agreement”). Effective 1 April 2024, Cogstate has re-acquired global rights to its
technology previously exclusively licensed to Eisai (excluding for Japan). Under the Amended Global License
Agreement, Eisai has been granted a non-exclusive license for Cognigram in the USA and CogMate in certain
Asian countries until August 2031.
Under the 10-year global (ex-Japan) amended global license agreement between Eisai and Cogstate executed
on 1 April 2024:
-
In addition to the upfront payments from Eisai of US$15 million, Cogstate is also due to receive an ongoing
royalty on revenue derived by Eisai from the sale of Cogstate technology. Over the course of the 10-year
global agreement, the contractual terms prescribe that the royalty payments shall not be less than an
additional $15 million ($9 million over years 1-5 and $6 million over years 6-10).
-
The full $30m (upfront payment of $15m plus the minimum royalties of $15m due over the course of the
global license agreement) is being amortised on a straight-line basis over 11 years (10-year term + 12 months
to commence). Actual cash royalties paid in each period will be the higher of (i) royalty amount calculated
based on sales of product or (ii) minimum annual cash royalty, which ramp up over the contract period.
FY24 Media Release | Page 3
FY24 Analysis
Clinical Trials
•
Clinical Trials revenue in FY24 increased 9% on PCP to $39.4m (FY23 $36.1m).
•
Contribution margin in FY24 increased to 55% (PCP 49%), resulting from May 2023 restructuring actions
and cost management, partially offset by low SW license mix.
•
The value of sales contracts executed in FY24 was $27m, down 21% on the $34m achieved in FY23.
Notwithstanding the decrease in value of sales contracts executed, important achievements for future
growth were achieved during the year, including:
o
the signing of four different phase 2 Alzheimer’s trials with four different large pharmaceutical
companies, three of which were new customers; and
o
sales growth in other key indications of sleep disorders, mood disorders and rare disease, which
combined grew 60% on PCP.
•
Cogstate continues to win work across a number of different indications, but Alzheimer’s disease and
associated dementias represent the bulk of revenue backlog. At 30 June 2024, 24% (30 June 2023: 14%)
of Clinical Trials revenue backlog related to indications other than Alzheimer’s disease.
•
With net new contract sales of $9.3m (gross $29.6m) as at 21st August 2024, Cogstate has Clinical Trials
contracted revenue backlog of $95.0m, with $31.4m expected to be realised as revenue in FY25 (PCP
$27.7m)
Healthcare
•
Healthcare revenue decreased in FY24 by 9% to $4.0m (PCP $4.4m). Healthcare primarily represents
revenue recognised in relation to Eisai royalty payments and has decreased following the strategic
renegotiation of the global licensing agreement, with Cogstate re-acquiring rights to Cogstate IP.
•
The earnings contribution declined 12% on PCP to $2.9m, representing a contribution margin of 72%. The
decline in margin is as a result of the reduction in Eisai royalty payments and from activities undertaken to
assess the go-to-market opportunities for the Healthcare market.
Future Revenue Backlog
The revenue backlog for both the Clinical Trials and Healthcare segments are highlighted in the table below.
Contracted Clinical Trials Revenue
Eisai License - Global
Eisai License - Japan
21-Aug-24
US$
30-Jun-24
US$
30-Jun-23
US$
94,978,205
15,430,385
515,467
110,924,057
85,643,497
15,430,385
515,467
101,589,349
97,951,714
34,035,590
615,658
132,602,962
FY24 Media Release | Page 4
Profit Before Tax
•
Profit before Tax grew 135% to $7.1m, up from PCP of $3.5m (before non-recurring restructuring charges).
•
Staff costs decreased 6% to $24.5m.
•
Profit growth resulted from the higher Clinical Trials revenue, lower salary costs and tight cost management
throughout FY24. Lower salary costs through FY24 were consistent with the savings anticipated when
Cogstate announced a staff restructure on 10 May 2023.
•
Full time equivalent staff numbers increased to 167.1 at 30 June 2024, up from 162.4 at 30 June 2023.
•
During FY24 $1.2m of internal software development costs were capitalised and $0.7m product
development costs were reimbursed (FY23 $1.1m).
•
Depreciation and amortisation expense of $2.7m in FY24, a 6% increase on PCP ($2.6m), reflecting the
ongoing investment in Cogstate technology.
Net Profit after tax
•
The Company reported a net profit after tax in FY24 of $5.4m compared to PCP of $3.6m.
•
A tax expense of $1.7m was recognised in FY24 compared to a tax benefit of $0.5m in FY23.
Cash Flow/Balance Sheet
•
•
The Company reported a positive Net Operating Cash Flow of $5.8m in FY24 compared to PCP $0.7m.
Operating cash flow included:
-
Cash receipts from customers of $40.6m for FY24, up from $39.6m in FY23, an increase of $1.0m.
-
Payment to suppliers and employees of $34.8m, down 11% from PCP of $39.0, largely a result of the
staff restructuring actions taken in May 2023.
As at 30 June 2024, Cogstate had gross cash of $30.1m, which included $0.7m of cash held on behalf of
customers for future pass-through payments. Excluding cash held for pass-through payments, Cogstate
had a net cash balance of $29.4m.
Share Buy-Back
As at 30 June 2024, the Group has purchased 4,393,730 ordinary shares for the total consideration of AUD$6.4m
(USD$4.2m). The buy-back was conducted in the ordinary course of trading at an average price per share of
AUD$1.46. The shares bought back were subsequently cancelled. The purchase price of each share acquired, was
allocated between share capital and retained earnings. The amount allocated to share capital per share acquired,
was equivalent to the average issue price of shares residing in share capital. The excess of purchase price over this
amount was allocated to retained earnings.
Number of Ordinary Shares
Acquired & Cancelled
Total Cost (AUD$)
Average Cost per
Share (AUD$)
30 June 2023
552,496
$862,802
1.56
30 June 2024
3,841,234
$5,541,422
1.44
4,393,730
$6,404,224
$1.46
Financial Year Ending
The Board has resolved to suspend the Share Buy-Back until further notice.
FY24 Media Release | Page 5
FY25 Outlook
FY25 has started encouragingly, with the execution of clinical trials sales contracts to the net value of $9.3m. Total
contracts executed by 21 August 2024 was $29.6m, though offset by the reorganisation of multiple ongoing phase
3 trials into a single larger trial.
The reorganisation of trials involved multiple phase 3 trials being conducted by the same customer, with the same
drug, but will now be undertaken under a single new protocol for a larger contract value. The reorganised trials
were first contracted during FY23 but uncertainty in respect of the program meant that Cogstate did not generate
significant revenue from the trials during either FY23 or FY24. The larger trial is currently in accelerated start-up
mode and is currently generating revenue for Cogstate.
Clinical Trials sales contracts in Alzheimer’s disease fell in FY24 to $13 million (FY23 $26m, FY22 $74m). During
FY25, Cogstate expects to see growth in this indication beyond the FY24 result, as supported by the contracts
already executed year to date as well as ongoing customer engagement in respect of planned Alzheimer’s
programs.
There also continues to be significant opportunity across other indications with particular emphasis in mood
disorders, sleep disorders and rare diseases.
Management expects to grow revenue and profit in FY25, but no specific guidance is provided at this time, pending
execution of sales contracts to provide greater certainty in respect of timing of revenue.
A further update will be provided at the company’s AGM on Wednesday 23 October 2024.
Cogstate Investor Webcast
Investors are invited to join Cogstate CEO, Brad O’Connor for a live webcast and Q&A presenting the annual financial
results today, Thursday 22 August 2024, at 8:30am Australian eastern standard time.
Investors can register via the following weblink to join the live event or receive the recording if unable to attend:
https://attendee.gotowebinar.com/register/1561058463047040604
Additionally, a video recording of the presentation will be available later today at the Cogstate Investor Centre
homepage: https://www.cogstate.com/investors/
This announcement was authorised for release by the Board of Directors of Cogstate Ltd.
FY24 Media Release | Page 6
About Cogstate
Cogstate Ltd (ASX:CGS) is the neuroscience technology company optimising brain health assessments to advance the
development of new medicines and to enable earlier clinical insights in healthcare. Cogstate technologies provide rapid, reliable
and highly sensitive computerised cognitive tests across a growing list of domains and support electronic clinical outcome
assessment (eCOA) solutions to replace costly and error-prone paper assessments with real-time data capture. The company’s
clinical trials solutions include quality assurance services for study endpoints that combine innovative operational approaches,
advanced analytics and scientific consulting. For over 20 years, Cogstate has proudly supported the leading-edge research needs
of biopharmaceutical companies and academic institutions and the clinical care needs of physicians and patients around the world.
In the Healthcare market, Cogstate seeks to provide primary care physicians and consumers with brief, accurate and scientifically
validated digital measures of cognition, with a focus on easy to use, self-administered tests that inform patients and save physician
time. In this market, Cogstate has partnered with pharmaceutical company, Eisai, to distribute Cogstate assessments in the USA
& Asia. For more information, please visit www.cogstate.com.
For further information contact:
Brad O’Connor, Chief Executive Officer, boconnor@cogstate.com
Important Notices
Past performance
Past performance is given for illustrative purposes only and should not be relied upon as (and is not) an indication of Cogstate's
views on its future financial performance or condition. Past performance of Cogstate cannot be relied upon as an indicator of (and
provides no guidance as to) the future performance of Cogstate. Nothing contained in this announcement nor any information
made available to you is, or shall be relied upon as, a promise, representation, warranty or guarantee, whether as to the past,
present or future.
Future performance and forward-looking statements
This announcement contains certain “forward-looking statements”. The words “expect”, “anticipate”, “estimate”, “intend”, “believe”,
“guidance”, “should”, “could”, “may”, “will”, “predict”, “plan” and other similar expressions are intended to identify forward-looking
statements. Indications of, and guidance on, future earnings and financial position and performance are also forward-looking
statements. Forward-looking statements, opinions and estimates provided in this announcement are based on assumptions and
contingencies that are subject to change without notice and involve known and unknown risks and uncertainties and other factors
that are beyond the control of Cogstate, its directors and management. Forward-looking statements are provided as a general
guide only and should not be relied upon as an indication or guarantee of future performance.
Actual results, performance or achievements may differ materially from those expressed or implied in such statements and any
projections and assumptions on which these statements are based. These statements may assume the success of Cogstate's
business strategies, including the that the results of any of those strategies will be realised in the period for which the forwardlooking statement may have been prepared or otherwise. For example, Cogstate's performance in any one financial period is
sensitive to whether or not contracts are signed in that period, or a subsequent period, and the rate of enrolment in trials of its
customers which are influenced by factors that are outside of Cogstate's control.
Readers are cautioned not to place undue reliance on forward-looking statements and except as required by law or regulation,
none of Cogstate, its representatives or advisers assumes any obligation to update these forward-looking statements. No
representation or warranty, express or implied, is made as to the accuracy, likelihood of achievement or reasonableness of any
forecasts, prospects, returns or statements in relation to future matters contained in this announcement. The forward-looking
statements are based on information available to Cogstate as at the date of this announcement. Except as required by law or
regulation (including the ASX Listing Rules), none of Cogstate, its representatives or advisers undertakes any obligation to provide
any additional or updated information, whether as a result of a change in expectations or assumptions, new information, future
events or results or otherwise. Indications of, and guidance or outlook on, future earnings or financial position or performance are
also forward-looking statements.
FY24 Media Release | Page 7
Share your feedback
Discover